<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Long-term outcome of multilayer flow modulator in aortic aneurysms</dc:title><dc:creator>Pintarić,	Karlo	(Avtor)
	</dc:creator><dc:creator>Boltežar,	Lučka	(Avtor)
	</dc:creator><dc:creator>Umek,	Nejc	(Avtor)
	</dc:creator><dc:creator>Kuhelj,	Dimitrij	(Avtor)
	</dc:creator><dc:subject>multilayer flow modulator</dc:subject><dc:subject>aortic aneurism</dc:subject><dc:subject>long-term follow up</dc:subject><dc:subject>volumetric measurements</dc:subject><dc:description>ckground. This retrospective study investigated the efficacy of endovascular treatment with multilayer flow modu-lators (MFMs) for treating aortic aneurysms in high-risk patients unsuitable for conventional treatments.Patients and methods. Conducted from 2011 to 2019 at a single center, this retrospective observational study in-cluded 17 patients who underwent endovascular treatment with MFMs. These patients were selected based on theirunsuitability for traditional surgical or endovascular procedures. The study involved meticulous pre-procedural plan-ning, precise implantation of MFMs, and follow-up using CT angiography. The primary focus was on volumetric andflow volume changes in aneurysms, along with traditional diameter measurements. Moreover, the technical successand post-procedural complications were also registered.Results. The technical success rate was 100%, and 30-day procedural complication rate was 17.6%. Post-treatmentassessments revealed that 11 out of 17 patients showed a decrease in flow volume within the aneurysm sac, indicativeof a favorable hemodynamic response. The median decrease in flow volume was 12 ml, with a median relative de-crease of 8%. However, there was no consistent reduction in aneurysm size; most aneurysms demonstrated a medianincrease in volume for 46 ml and median increase in diameter for 18 mm.Conclusions. While MFMs offer a potential alternative for high-risk aortic aneurysm patients, their effectiveness in pre-venting aneurysm expansion is limited. The results suggest that MFMs can provide a stable hemodynamic environmentbut do not reliably reduce aneurysm size. This underscores the need for ongoing vigilance and long-term monitoringin patients treated with this technology</dc:description><dc:publisher>Association of Radiology and Oncology</dc:publisher><dc:date>2024</dc:date><dc:date>2026-06-26 10:21:15</dc:date><dc:type>Neznano</dc:type><dc:identifier>30454</dc:identifier><dc:identifier>UDK: 616-006</dc:identifier><dc:identifier>ISSN pri članku: 1318-2099</dc:identifier><dc:identifier>DOI: 10.2478/raon-2024-0021</dc:identifier><dc:identifier>COBISS_ID: 195722755</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language></metadata>
